N,N'-dimethyl-N-propionylurea | 122058-79-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机碳酸及其衍生物
• 英文名称: N,N'-dimethyl-N-propionylurea
• 英文别名: N-methyl-N-(methylcarbamoyl)propanamide
• CAS: 122058-79-1
• 化学式: C₆H₁₂N₂O₂
• mdl: MFCD19224651
• 分子量: 144.173
• InChiKey: NWSJCLKFSKNLLT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.666
• 拓扑面积：
  49.4
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N,N'-dimethyl-N-propionylurea 在 五氯化磷 、 二氧化硫 作用下， 以 苯 为溶剂， 反应 240.0h， 生成 4,6-dichloro-1,2,3,4-tetrahydro-1,3,5-trimethyl-2-oxo-1,3,4-diazaphosphorine 4-oxide
  参考文献：
  名称：

  Dmitrichenko, M. Yu.; Rozinov, V. G.; Donskikh, V. I., Journal of general chemistry of the USSR, 1988, vol. 58, # 10, p. 2004 - 2012

  摘要：

  DOI：
• 作为产物：
  描述：

  1,3-二甲基脲 、 丙酰氯 以 苯 为溶剂， 以92%的产率得到N,N'-dimethyl-N-propionylurea
  参考文献：
  名称：

  Dmitrichenko, M. Yu.; Rozinov, V. G.; Donskikh, V. I., Journal of general chemistry of the USSR, 1988, vol. 58, # 10, p. 2004 - 2012

  摘要：

  DOI：

文献信息

• Pyridinone Pyrazole Urea and Pyrimidinone Pyrazole Urea Derivatives
  申请人：Devadas Balekudru

  公开号：US20090270350A1

  公开（公告）日：2009-10-29

  This invention is directed generally to substituted pyridinone and pyrimidinone compounds that generally inhibit p38 kinase, TNF, and/or cyclooxygeπase activity. Such substituted pyridinone and pyrimidinone compounds include compounds generally corresponding in structure to the following formula: wherein Z, n, R 1 , R 2a , R 2b , R 2c , R 2d , R 2e , R 3a , R 3b , R 3c , R 3d , R 4 , R 5 , R 6 , R 7a , R 7b , R 7c , R 7d and R 7e are as defined in this specification. This invention also is directed to compositions of such substituted pyridinones and pyrimidinones (particularly pharmaceutical compositions), and methods for treating disorders (typically pathological disorders) associated with p38 kinase activity, TNF activity, and/or cyclooxygenase-2 activity.

  本发明通常涉及取代的吡啶酮和嘧啶酮化合物，它们通常抑制p38激酶、TNF和/或环氧合酶活性。这些取代的吡啶酮和嘧啶酮化合物包括通常对应于以下结构公式的化合物：其中Z、n、R1、R2a、R2b、R2c、R2d、R2e、R3a、R3b、R3c、R3d、R4、R5、R6、R7a、R7b、R7c、R7d和R7e如本说明书所定义。本发明还涉及这些取代的吡啶酮和嘧啶酮（特别是药物组成物）的组成物，以及用于治疗与p38激酶活性、TNF活性和/或环氧合酶-2活性相关的疾病（通常是病理性疾病）的方法。
• Solvent borne non-isocyanate curable two-components coating composition
  申请人：Guangdong Huarun Paints Co., Ltd.

  公开号：US11130882B2

  公开（公告）日：2021-09-28

  The present disclosure is directed to a solvent borne non-isocyanate curable two-components coating composition, comprising: component a) a film-forming resin composition comprising a resin component having carboxyl functional groups and hydroxyl functional groups and having an acid value of at least 23 mg KOH/g resin; and component b) an aromatic polycarbodiimide having two or more —N═C═N— moieties, wherein the carboxyl functional groups of the resin component and the —N═C═N— moieties present in the aromatic polycarbodiimide have a molar ratio in the range of 1:2 to 2:1, preferably in the range of 1:1 to 2:1; and wherein the coating composition comprises less than 1 wt % of water relative to the total weight of the coating composition. The present disclosure is also directed to an article comprising a substrate and a coating disposed thereon formed by the above solvent borne non-isocyanate curable two-components coating composition.

  本公开涉及一种溶剂型非异氰酸酯固化双组分涂料组合物，包括组分 a）成膜树脂组合物，包括具有羧基官能团和羟基官能团且酸值至少为 23 mg KOH/g 树脂的树脂组分；以及组分 b）具有两个或两个以上 -N═C═N- 基团的芳香族聚碳二亚胺，其中树脂组分的羧基官能团和芳香族聚碳二亚胺中的 -N═C═N- 基团的摩尔比在 1：2至2:1的范围内，优选在1:1至2:1的范围内；并且其中涂层组合物包含相对于涂层组合物总重量小于1重量％的水。本公开还涉及一种物品，该物品包括基材和由上述溶剂型非异氰酸酯固化双组分涂料组合物形成的涂层。
• DMITRICHENKO, M. YU.;ROZINOV, V. G.;DONSKIX, V. I.;RATOVSKIJ, G. V.;SERGI+, ZH. OBSHCH. XIMII, 58,(1988) N 10, S. 2252-2261
  作者：DMITRICHENKO, M. YU.、ROZINOV, V. G.、DONSKIX, V. I.、RATOVSKIJ, G. V.、SERGI+

  DOI：——

  日期：——
• POLYMER AND ORGANIC SOLAR CELL COMPRISING SAME
  申请人：LG Chem, Ltd.

  公开号：EP3121211B1

  公开（公告）日：2021-02-24
• CYCLOSPORIN DERIVATIVES FOR TREATING INFLAMMATORY DISEASES AND CONDITIONS
  申请人：Garst Michael E.

  公开号：US20100305037A1

  公开（公告）日：2010-12-02

  The present invention provides a method for the treatment of inflammatory diseases and/or conditions, e.g. allergic conjunctivitis, uveitis or phacoanaphylactic endophthalmitis in an eye of a mammal, said method comprising administering to said mammal in need of treatment a therapeutically effective amount of a novel cyclosporin A derivative selected from the group consisting of compounds represented by the formula: wherein R 1 is S-Alk-R wherein Alk is an alkylene linkage, preferably a methylene or poly methylene linkage, or a polyalkenylene linkage, e.g. a C 3 to C 6 alkenylenyl linkage and R is a hydrogen or a unsubstituted or substituted hydrocarbyl group.